Expert Interview
A Second Look: Discussing the potential of immunotherapy, durvalumab, plus PARP inhibitor, olaparib, as maintenance therapy following platinum-based chemotherapy in patients with endometrial cancer.
Ticker(s): AZNInstitution: Kaiser Permanente
- Medical oncologist at KP
- Has 72 active chemo pts on my practice as of today at least 55 are ovarian
- Very familiar with SORAYA trial and mirvetuximab already has one pt on it
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
